Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.

Advances in experimental medicine and biology - 1 Jan 2016

Fredebohm Johannes, Mehnert Daniel H, Löber Ann-Kathrin, Holtrup Frank, van Rahden Vanessa, Angenendt Philipp, Diehl Frank

Abstract excerpt

We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay was applied to plasma samples of GIST patients before and after treatment with regorafenib (GRID III trial) and mutations at known and novel sites of potential secondary resistance were identified.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Neoplasms
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Outcome Assessment, Health Care

Share to Phenylurea Compounds

Share to Pyridines

Share to Pyrroles

Share to Sunitinib

Source

Identifiers

PMID: 27753042
DOI: 10.1007/978-3-319-42044-8_34

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.PMID 27753042Read ↗

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.Semantic proximity Read ↗

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.Semantic proximity Read ↗

Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.Semantic proximity Read ↗

Clinical performance evaluation of a highly sensitive Safe-SeqS plasma circulating-tumor DNA assay for the detection of RAS and BRAF V600E mutations in metastatic colorectal cancerSemantic proximity Read ↗

Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).Semantic proximity Read ↗

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.Semantic proximity Read ↗

Novel hybridization- and tag-based error-corrected method for sensitive ctDNA mutation detection using ion semiconductor sequencing.Semantic proximity Read ↗

Genomic profiling in GIST: Implications in clinical outcome and future challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.